Naoaki Sakata

Dr. Naoaki Sakata

Department of Regenerative Medicine and Transplantation, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2004 in Biomaterials
Verified
Journal Article
Closed access
MQMeirigeng Qi
Meirigeng Qi
YGYuanjun Gu
Yuanjun Gu
NSNaoaki Sakata
Naoaki Sakata
DKDohoon Kim
Dohoon Kim
YSYasumasa Shirouzu
Yasumasa Shirouzu
KIKazutomo Inoue
Kazutomo Inoue

2 September 2013 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Closed access
PDF file
NSNaoaki Sakata
Naoaki Sakata
TATakeshi Aoki
Takeshi Aoki
GYGumpei Yoshimatsu
Gumpei Yoshimatsu
HTHaruyuki Tsuchiya
Haruyuki Tsuchiya
THTatsuo Hata
Tatsuo Hata
MUMichiaki Unno
Michiaki Unno

27 May 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Rieko OhkiRieko Ohki
Rieko Ohki
KSKozue Saito
Kozue Saito
YCYu Chen
Yu Chen
TKTatsuya Kawase
Tatsuya Kawase
NHNobuyoshi Hiraoka
Nobuyoshi Hiraoka
HNHitoshi Nakagama
Hitoshi Nakagama
Significance: Pancreatic neuroendocrine tumors (PanNETs) are a rare pathology, and molecular mechanisms underlying their development have not been well defined. This article shows that a two-hit inactivation of the PHLDA3 gene is required for PanNET development: methylation of the locus and loss of heterozygosity. PHLDA3 functions as a suppressor of PanNETs via repression of Akt activity and downstream Akt-regulated biological processes. In addition, the tumor-suppressing pathway mediated by MEN1, a well known suppressor of PanNETs, is dependent on the pathway mediated by PHLDA3, and inactivation of PHLDA3 and MEN1 cooperatively contribute to PanNET development. A novel PHLDA3-mediated pathway of tumor suppression that is important in the development of PanNETs is demonstrated, and the findings may contribute to personalized medicine of PanNET patients.

27 March 2010 in Transplantation
Verified
Journal Article
Closed access
NSNaoaki Sakata
Naoaki Sakata
NCNathaniel K. Chan
Nathaniel K. Chan
JCJohn Chrisler
John Chrisler
AOAndre Obenaus
Andre Obenaus
EHEba Hathout
Eba Hathout
Background. To test the angiogenesis-promoting effects of bone marrow cells when cotransplanted with islets. Methods. Streptozotocin-induced diabetic BALB/c mice were transplanted syngeneically under the kidney capsule: (1) 200 islets, (2) 1 to 5×106 bone marrow cells, or (3) 200 islets and 1 to 5×106 bone marrow cells. All mice were evaluated for blood glucose, serum insulin, and glucose tolerance up to postoperative day (POD) 28, and a subset was monitored for 3 months after transplantation. Histologic assessment was performed at PODs 3, 7, 14, 28, and 84 for the detection of von Willebrand factor (vWF), vascular endothelial growth factor (VEGF), insulin, cluster of differentiation-34, and pancreatic duodenal homeobox-1 (PDX-1) protein. Results. Blood glucose was the lowest and serum insulin was the highest in the islet+bone marrow group at POD 7. Blood glucose was significantly lower in the islet+bone marrow group relative to the islet only group after 63 days of transplantation (P<0.05). Significantly more new periislet vessels were detected in the islet+bone marrow group compared with the islet group (P<0.05). Vascular endothelial growth factor staining was more prominent in bone marrow than in islets (P<0.05). Pancreatic duodenal homeobox-1-positive areas were identified in bone marrow cells with an increase in staining over time. However, there were no normoglycemic mice and no insulin-positive cells in the bone marrow alone group. Conclusions. Cotransplantation of bone marrow cells with islets is associated with enhanced islet graft vascularization and function.

1 November 2007 in Pancreas
Verified
Journal Article
Closed access
MIMasaharu Ishida
Masaharu Ishida
SEShinichi Egawa
Shinichi Egawa
TATakeshi Aoki
Takeshi Aoki
NSNaoaki Sakata
Naoaki Sakata
YMYukio Mikami
Yukio Mikami
TFToru Furukawa
Toru Furukawa
Intraductal papillary-mucinous neoplasm (IPMN) of the pancreas encompasses a spectrum of neoplasms with both morphological and immunohistochemical variations of mucin glycoproteins. Recently, a consensus nomenclature and criteria were histologically defined for classifying these variants of IPMNs into gastric, intestinal, pancreatobiliary, and oncocytic types. The purpose of this study was to determine associations between the histological types and clinicopathological features in patients with IPMN. Sixty-one patients with IPMN operated upon at Tohoku University Hospital between 1988 and 2006 were retrospectively analyzed. Our series included 27 gastric-, 29 intestinal-, 4 pancreatobiliary-, and 1 oncocytic-type IPMNs. Statistically, the types of IPMN were significantly associated with the histological diagnoses, macroscopic types, and survival of the patients. Characteristically, the gastric-type IPMNs were likely to be diagnosed as benign, to be confined to branch ducts, and to have fair prognoses. On the other hand, the intestinal-type IPMNs were likely to be diagnosed as malignant, occupy the main duct, and have poor prognoses. Because of the small number of pancreatobiliary-type IPMNs and only 1 case of oncocytic-type IPMN, we were unable to determine any of their clinicopathological characteristics in our series. Evaluation of the histological types of IPMN may help to predict the clinical course of patients with IPMN and to design improved clinical management for these patients.

1 January 2012 in World Journal of Gastrointestinal Pathophysiology
Verified
Journal Article
Open access
NSNaoaki Sakata
Naoaki Sakata
SSShoichiro Sumi
Shoichiro Sumi
GYGumpei Yoshimatsu
Gumpei Yoshimatsu
MGMasafumi Goto
Masafumi Goto
SEShinichi Egawa
Shinichi Egawa
MUMichiaki Unno
Michiaki Unno
Encapsulated islets transplantation: Past, present and future